ATE113059T1 - Nukleosid-derivate. - Google Patents

Nukleosid-derivate.

Info

Publication number: ATE113059T1
Authority: AT; Austria
Prior art keywords: group; alkyl; unbranched; branched; formula
Prior art date: 1987-06-24

Application number

AT88905594T

Other languages

English (en)

Inventor

Jim Haralambidis

Original Assignee

Florey Howard Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-06-24

Filing date

1988-06-24

Publication date

1994-11-15

1988-06-24 Application filed by Florey Howard Inst filed Critical Florey Howard Inst

1994-11-15 Application granted granted Critical

1994-11-15 Publication of ATE113059T1 publication Critical patent/ATE113059T1/de

Links

150000003833 nucleoside derivatives Chemical class 0.000 title abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 3
125000006239 protecting group Chemical group 0.000 abstract 3
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
239000003550 marker Substances 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
230000002285 radioactive effect Effects 0.000 abstract 2
229910019142 PO4 Inorganic materials 0.000 abstract 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
125000006245 phosphate protecting group Chemical group 0.000 abstract 1
SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
238000012163 sequencing technique Methods 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Saccharide Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT88905594T 1987-06-24 1988-06-24 Nukleosid-derivate. ATE113059T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AUPI266687		1987-06-24

Publications (1)

Publication Number	Publication Date
ATE113059T1 true ATE113059T1 (de)	1994-11-15

Family

ID=3772261

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT88905594T ATE113059T1 (de)	1987-06-24	1988-06-24	Nukleosid-derivate.

Country Status (9)

Country	Link
US (1)	US5552540A (de)
EP (1)	EP0366685B1 (de)
JP (1)	JP2828642B2 (de)
AT (1)	ATE113059T1 (de)
AU (1)	AU598946B2 (de)
CA (1)	CA1340032C (de)
DE (1)	DE3851889T2 (de)
NZ (1)	NZ225176A (de)
WO (1)	WO1988010264A1 (de)

Families Citing this family (876)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4948882A (en) *	1983-02-22	1990-08-14	Syngene, Inc.	Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US5047519A (en) *	1986-07-02	1991-09-10	E. I. Du Pont De Nemours And Company	Alkynylamino-nucleotides
USRE38416E1 (en)	1988-09-28	2004-02-03	Epoch Biosciences, Inc.	Cross-linking oligonucleotides
US5824796A (en) *	1988-09-28	1998-10-20	Epoch Pharmaceuticals, Inc.	Cross-linking oligonucleotides
US5849482A (en) *	1988-09-28	1998-12-15	Epoch Pharmaceuticals, Inc.	Crosslinking oligonucleotides
FR2642074B1 (fr) *	1989-01-20	1994-04-29	Oris Ind	Derives de molecules polyhydroxylees permettant l'introduction d'au moins une ramification dans un oligonucleotide
WO1990014353A1 (en) *	1989-05-18	1990-11-29	Microprobe Corporation	Crosslinking oligonucleotides
US6013434A (en) *	1989-12-22	2000-01-11	Howard Florey Institute Of Experimental Physiology And Medicine	Oligonucleotide-polyamide conjugates
WO1993024511A1 (en) *	1992-05-29	1993-12-09	Howard Florey Institute Of Experimental Physiology And Medicine	Oligonucleotide-polyamide conjugates
DE4102289A1 (de) *	1991-01-26	1992-07-30	Bayer Ag	Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine
US6136601A (en) *	1991-08-21	2000-10-24	Epoch Pharmaceuticals, Inc.	Targeted mutagenesis in living cells using modified oligonucleotides
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
US6235887B1 (en) *	1991-11-26	2001-05-22	Isis Pharmaceuticals, Inc.	Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
AU678968B2 (en) *	1992-05-29	1997-06-19	Howard Florey Institute Of Experimental Physiology And Medicine	Oligonucleotide-polyamide conjugates
CA2170869C (en)	1993-09-03	1999-09-14	Phillip Dan Cook	Amine-derivatized nucleosides and oligonucleosides
US6028190A (en)	1994-02-01	2000-02-22	The Regents Of The University Of California	Probes labeled with energy transfer coupled dyes
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
US6008373A (en)	1995-06-07	1999-12-28	Carnegie Mellon University	Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
US5945526A (en) *	1996-05-03	1999-08-31	Perkin-Elmer Corporation	Energy transfer dyes with enhanced fluorescence
US7388092B2 (en)	1996-05-03	2008-06-17	Applera Corporation	Oligonucleotides and analogs labeled with energy transfer dyes
US7825237B2 (en) *	1996-05-03	2010-11-02	Applied Biosystems, Llc	Oligonucleotides and analogs labeled with energy transfer dyes
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
SE9701783D0 (sv) *	1997-05-14	1997-05-14	Marek Kwiatkowski	In situ synthesis of oligonucleotides of inverse orientation
WO1999001579A1 (en)	1997-07-01	1999-01-14	Isis Pharmaceuticals, Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6007992A (en) *	1997-11-10	1999-12-28	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US6028183A (en) *	1997-11-07	2000-02-22	Gilead Sciences, Inc.	Pyrimidine derivatives and oligonucleotides containing same
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US7321828B2 (en)	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
WO1999060012A1 (en)	1998-05-21	1999-11-25	Isis Pharmaceuticals, Inc.	Compositions and methods for non-parenteral delivery of oligonucleotides
US6841539B1 (en)	1998-05-21	2005-01-11	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6358684B1 (en) *	1999-08-27	2002-03-19	Pe Corporation	UV excitable fluorescent energy transfer dyes
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US6436641B1 (en) *	2000-04-17	2002-08-20	Visible Genetics Inc.	Method and apparatus for DNA sequencing
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
AU9684601A (en)	2000-10-12	2002-04-22	Univ Rochester	Compositions that inhibit proliferation of cancer cells
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US7083951B2 (en) *	2001-02-14	2006-08-01	The Regents Of The University Of California	Flow cytometric detection method for DNA samples
US6573051B2 (en) *	2001-03-09	2003-06-03	Molecular Staging, Inc.	Open circle probes with intramolecular stem structures
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
KR100576674B1 (ko)	2001-06-20	2006-05-10	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
AU2002315393A1 (en)	2001-06-21	2003-01-08	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
ES2431929T3 (es)	2001-09-18	2013-11-28	Genentech, Inc.	Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
EP2270231A3 (de)	2001-10-09	2011-04-27	ISIS Pharmaceuticals, Inc.	Antisense Modulation der Expression von insulin-like growth factor binding protein 5
GB0128526D0 (en) *	2001-11-29	2002-01-23	Amersham Pharm Biotech Uk Ltd	Nucleotide analogues
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
EP2067472A1 (de)	2002-01-02	2009-06-10	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US7553619B2 (en)	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
CA2481507A1 (en)	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
EP2116604A1 (de)	2002-08-05	2009-11-11	University of Rochester	Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
JP2006500030A (ja)	2002-09-20	2006-01-05	イェールユニバーシティ	リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
AU2003278957A1 (en)	2002-09-26	2004-04-23	Amgen, Inc.	Modulation of forkhead box o1a expression
WO2004043979A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
CA2504720C (en)	2002-11-05	2013-12-24	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP2336318B1 (de)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense-modulation von apolipoprotein-b-expression
ES2417879T3 (es)	2002-11-13	2013-08-09	Genzyme Corporation	Modulación antisentido de la expresión de la apolipoproteína B
CN100594037C (zh)	2002-11-15	2010-03-17	Musc研究发展基金会	通过补体受体2定向的补体调节剂
US7754450B2 (en)	2002-11-15	2010-07-13	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
AU2003294462C1 (en)	2002-11-21	2011-06-30	University Of Utah Research Foundation	Purinergic modulation of smell
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US20040121338A1 (en) *	2002-12-19	2004-06-24	Alsmadi Osama A.	Real-time detection of rolling circle amplification products
JP4886298B2 (ja)	2002-12-20	2012-02-29	キアゲンゲゼルシャフトミットベシュレンクテルハフツング	核酸増幅
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
US6977153B2 (en) *	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
US7781163B2 (en) *	2003-01-08	2010-08-24	Lesley Davenport	G-quadruplex binding assays and compounds therefor
US7468356B2 (en)	2003-02-11	2008-12-23	Antisense Therapeutics Ltd.	Modulation of insulin like growth factor I receptor expression
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
US7276599B2 (en)	2003-06-02	2007-10-02	Isis Pharmaceuticals, Inc.	Oligonucleotide synthesis with alternative solvents
CN1984921B (zh)	2003-06-03	2010-06-16	Isis药物公司	存活蛋白表达的调节
WO2005014782A2 (en)	2003-06-13	2005-02-17	Alnylam Europe Ag.,	Double-stranded ribonucleic acid with increased effectiveness in an organism
EP2530157B1 (de)	2003-07-31	2016-09-28	Regulus Therapeutics Inc.	Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
NZ592039A (en)	2003-08-27	2013-03-28	Ophthotech Corp	Combination therapy for the treatment of ocular neovascular disorders
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
JP5379347B2 (ja)	2003-09-18	2013-12-25	アイシスファーマシューティカルズ，インコーポレーテッド	４’−チオヌクレオシドおよびオリゴマー化合物
SG146682A1 (en)	2003-09-18	2008-10-30	Isis Pharmaceuticals Inc	Modulation of eif4e expression
US7662929B2 (en)	2003-10-10	2010-02-16	Alchemia Oncology Pty Limited	Antibody that specifically binds hyaluronan synthase
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
PL2295073T3 (pl)	2003-11-17	2014-09-30	Genentech Inc	Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego
WO2005071080A2 (en)	2004-01-20	2005-08-04	Isis Pharmaceuticals, Inc.	Modulation of glucocorticoid receptor expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en)	2004-03-15	2014-07-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of RNA by RNase H
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
JP2007531794A (ja)	2004-04-05	2007-11-08	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
CA2562151C (en)	2004-04-30	2016-09-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a c5-modified pyrimidine
DK1773872T3 (en)	2004-05-21	2017-05-08	Uab Res Found	VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7427675B2 (en)	2004-08-23	2008-09-23	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006032143A1 (en)	2004-09-23	2006-03-30	Arc Pharmaceuticals, Inc.	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
EP1869076A2 (de)	2005-03-10	2007-12-26	Genentech, Inc.	Verfahren und zusammensetzungen zur modulation der gefässintegrität
US7476733B2 (en)	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8309303B2 (en)	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
JP5329949B2 (ja)	2005-05-31	2013-10-30	エコーレポリテクニークフェデラーレデローザンヌ	遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
MY144014A (en)	2005-08-11	2011-07-29	Synthetic Genomics Inc	Method for in vitro recombination
US20100015604A1 (en)	2005-08-17	2010-01-21	Evriklia Lianidou	Composition and method for determination of ck19 expression
WO2007027775A2 (en)	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
KR20080074101A (ko)	2005-09-19	2008-08-12	존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨	글루카곤 수용체 발현의 조절
CA2623772A1 (en)	2005-09-19	2007-03-29	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Modulation of glucocorticoid receptor expression
EP2395076A1 (de)	2005-10-14	2011-12-14	MUSC Foundation For Research Development	Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
AU2006305886C1 (en)	2005-10-28	2011-03-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of huntingtin gene
WO2007056331A2 (en)	2005-11-09	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
AU2006318194B2 (en)	2005-11-21	2012-08-09	Isis Pharmaceuticals, Inc.	Modulation of eiF4E-BP2 expression
EP1974052A2 (de) *	2005-12-21	2008-10-01	Yale University	Verfahren und zusammensetzungen in verbindung mit der modulation von riboschaltern
JP5713377B2 (ja)	2005-12-28	2015-05-07	ザスクリプスリサーチインスティテュート	薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
US8129515B2 (en)	2006-01-27	2012-03-06	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of microRNAs
ES2351674T3 (es)	2006-01-27	2011-02-09	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
CA2647728C (en)	2006-03-31	2014-12-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of eg5 gene
MX2008014005A (es)	2006-05-03	2009-01-27	Baltic Technology Dev Ltd	Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.
DK2021472T3 (da)	2006-05-05	2011-09-19	Isis Pharmaceuticals Inc	Forbindelser og fremgangsmåder til modulering af genekspression
CA2651453C (en)	2006-05-11	2014-10-14	Isis Pharmaceuticals, Inc.	5'-modified bicyclic nucleic acid analogs
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
CA2652770A1 (en)	2006-05-19	2007-11-29	Alnylam Pharmaceuticals, Inc.	Rnai modulation of aha and therapeutic uses thereof
CA2653451C (en)	2006-05-22	2015-12-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of ikk-b gene
WO2008097328A2 (en) *	2006-06-23	2008-08-14	Northwestern University	Asymmetric functionalized nanoparticles and methods of use
WO2008011473A2 (en)	2006-07-19	2008-01-24	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to hbxip
WO2008033866A2 (en) *	2006-09-11	2008-03-20	Yale University	Methods and compositions for the use of lysine riboswitches
US20100099858A1 (en) *	2006-09-28	2010-04-22	Mirkin Chad A	Maximizing Oligonucleotide Loading on Gold Nanoparticle
JP5560039B2 (ja)	2006-10-05	2014-07-23	マサチューセッツインスティテュートオブテクノロジー	ハイスループット分析のための多機能のコード化された粒子
EP2104516B1 (de)	2006-11-01	2015-01-07	University of Rochester	Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
CN101600451A (zh)	2006-12-11	2009-12-09	犹他大学研究基金会	用于治疗病理性血管生成和血管通透性的组合物和方法
AU2008212820B2 (en)	2007-02-09	2014-01-30	Northwestern University	Particles for detecting intracellular targets
JP2010521977A (ja)	2007-03-22	2010-07-01	イェールユニバーシティー	オルタナティブスプライシングを調節するリボスイッチに関する方法および組成物
JP5350360B2 (ja)	2007-03-29	2013-11-27	アルナイラムファーマシューティカルズ，インコーポレイテッド	エボラ由来の遺伝子の発現を阻害するための組成物および方法
WO2008156987A2 (en)	2007-05-29	2008-12-24	Yale University	Riboswitches and methods and compositions for use of and with riboswitches
WO2008150884A1 (en) *	2007-05-29	2008-12-11	Yale University	Methods and compositions related to riboswitches that control alternative splicing and rna processing
AU2008259907B2 (en)	2007-05-30	2014-12-04	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
EP2170917B1 (de)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	Über n-substituiertes aminomethylen verbrückte, bicyclische nukleinsäureanaloga
US7807372B2 (en) *	2007-06-04	2010-10-05	Northwestern University	Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
EP2173760B2 (de)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Carbozyklische bizyklische nukleinsäureanaloga
EP2176280B2 (de) *	2007-07-05	2015-06-24	Isis Pharmaceuticals, Inc.	6-disubstituierte bizyklische nukleinsäureanaloga
WO2009023855A2 (en)	2007-08-15	2009-02-19	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
US8557767B2 (en)	2007-08-28	2013-10-15	Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2195331B1 (de)	2007-08-28	2013-11-20	Uab Research Foundation	Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren
US8445217B2 (en)	2007-09-20	2013-05-21	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en)	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
EP2222851B1 (de)	2007-11-20	2017-06-28	Ionis Pharmaceuticals, Inc.	Modulation der cd40-expression
EP2848688A1 (de)	2007-12-10	2015-03-18	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
JP5749494B2 (ja)	2008-01-02	2015-07-15	テクミラファーマシューティカルズコーポレイション	核酸の送達のための改善された組成物および方法
WO2009100320A2 (en) *	2008-02-07	2009-08-13	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
AU2009221775B2 (en)	2008-03-05	2015-05-07	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of Eg5 and VEGF genes
US8426378B2 (en) *	2008-03-21	2013-04-23	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucelosides and methods for their use
US8846639B2 (en) *	2008-04-04	2014-09-30	Isis Pharmaceutical, Inc.	Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
WO2009124238A1 (en) *	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
DK2281042T3 (en)	2008-04-18	2015-11-09	Baxter Int	Microsphere-based composition for preventing and / or deletion of starting autoimmune diabetes
CA2728467A1 (en) *	2008-07-15	2010-01-21	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of tgf-beta receptor genes
SG196769A1 (en)	2008-08-25	2014-02-13	Excaliard Pharmaceuticals Inc	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
JP2012502040A (ja) *	2008-09-02	2012-01-26	アルニラムファーマスーティカルズインコーポレイテッド	三リン酸塩オリゴヌクレオチドの合成方法および誘導体
EP3208337A1 (de)	2008-09-02	2017-08-23	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
US8501805B2 (en) *	2008-09-24	2013-08-06	Isis Pharmaceuticals, Inc.	Substituted alpha-L-bicyclic nucleosides
EP2361256B1 (de)	2008-09-24	2013-04-10	Isis Pharmaceuticals, Inc.	Cyclohexenylverbindungen als nukleinsäureanaloga
WO2010036962A1 (en)	2008-09-25	2010-04-01	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
JP5777519B2 (ja)	2008-10-09	2015-09-09	テクミラファーマシューティカルズコーポレイション	改良されたアミノ脂質および核酸の送達方法
EP2379084B1 (de)	2008-10-15	2017-11-22	Ionis Pharmaceuticals, Inc.	Modulation der expression von faktor 11
AU2009307677C1 (en)	2008-10-20	2022-09-22	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of transthyretin
WO2010048585A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
CA2741294C (en)	2008-10-24	2018-04-24	Isis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
RU2011124146A (ru) *	2008-11-17	2012-12-27	Ф.Хоффманн-Ля Рош Аг	Композиции и способы подавления экспрессии генов фактора vii
DK2365803T3 (en)	2008-11-24	2018-01-22	Univ Northwestern	POLYVALENT RNA NANOPARTICLE COMPOSITIONS
SG171914A1 (en)	2008-12-02	2011-07-28	Chiralgen Ltd	Method for the synthesis of phosphorus atom modified nucleic acids
CN102307997B (zh)	2008-12-04	2018-03-30	库尔纳公司	通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病
KR101829469B1 (ko)	2008-12-04	2018-03-30	큐알엔에이, 인크.	Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
KR101866152B1 (ko)	2008-12-04	2018-06-08	큐알엔에이, 인크.	종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
CA2746514C (en)	2008-12-10	2018-11-27	Alnylam Pharmaceuticals, Inc.	Gnaq targeted dsrna compositions and methods for inhibiting expression
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
EP2391733A1 (de)	2009-01-27	2011-12-07	QIAGEN Gaithersburg, Inc.	Thermophile-helikase-abhängige amplifikationstechnik mit homogenem fluoreszenzendpunktnachweis
US20120101148A1 (en)	2009-01-29	2012-04-26	Alnylam Pharmaceuticals, Inc.	lipid formulation
BRPI1008109A2 (pt) *	2009-02-03	2015-08-25	Hoffmann La Roche	"composições e métodos para a inibição de expressão de genes de ptp1b".
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
WO2010093904A2 (en)	2009-02-12	2010-08-19	Curna, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010093906A2 (en)	2009-02-12	2010-08-19	Curna, Inc.	Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
US20110319317A1 (en)	2009-03-04	2011-12-29	Opko Curna, Llc	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
AU2010223967B2 (en)	2009-03-12	2015-07-30	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2408919B1 (de)	2009-03-16	2017-10-18	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
EP2408920B1 (de)	2009-03-17	2017-03-08	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
CN102449170A (zh)	2009-04-15	2012-05-09	西北大学	寡核苷酸功能化的纳米颗粒的递送
EP3248618A1 (de)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
EP2424987B1 (de)	2009-05-01	2017-11-15	CuRNA, Inc.	Behandlung von hämoglobin (hbf / hbg) verwandten krankheiten durch die inhibition des natürlichen antisense transcripts zu hbf / hbg
CA2760706C (en)	2009-05-05	2019-08-06	Alnylam Pharmaceuticals, Inc.	Methods of delivering oligonucleotides to immune cells
SG176553A1 (en)	2009-05-05	2012-01-30	Muthiah Manoharan	Lipid compositions
WO2010129746A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
AU2010247389A1 (en) *	2009-05-15	2011-10-27	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of glucocorticoid receptor (GCR) genes
US20120107331A1 (en)	2009-05-15	2012-05-03	Yale University	Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
WO2010135329A2 (en)	2009-05-18	2010-11-25	Curna, Inc.	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
CN102549158B (zh)	2009-05-22	2017-09-26	库尔纳公司	通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
CA2764683A1 (en)	2009-05-28	2010-12-02	Joseph Collard	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
TR201811076T4 (tr)	2009-06-10	2018-08-27	Arbutus Biopharma Corp	Geliştirilmiş lipit formulasyonu.
CN102612560B (zh)	2009-06-16	2017-10-17	库尔纳公司	通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
JP5944311B2 (ja)	2009-06-16	2016-07-05	クルナ・インコーポレーテッド	コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
US8859515B2 (en)	2009-06-24	2014-10-14	Curna, Inc.	Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2
CA2765815A1 (en)	2009-06-26	2010-12-29	Opko Curna, Llc	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
EP2451461A4 (de)	2009-07-06	2013-05-29	Ontorii Inc	Neuartige nukleinsäure-prodrugs und verwendungsverfahren dafür
DK2459743T3 (da) *	2009-07-30	2017-11-06	Hoffmann La Roche	Sæt af oligonukleotidprober såvel som fremgangsmåder og anvendelser relateret dertil
JP6128848B2 (ja)	2009-08-05	2017-05-17	クルナ・インコーポレーテッド	インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
US9012421B2 (en)	2009-08-06	2015-04-21	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
EP2464336A4 (de)	2009-08-14	2013-11-20	Alnylam Pharmaceuticals Inc	Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
WO2011022420A1 (en)	2009-08-17	2011-02-24	Yale University	Methylation biomarkers and methods of use
KR101892760B1 (ko)	2009-08-25	2018-08-28	큐알엔에이, 인크.	ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
BR112012009409A2 (pt)	2009-10-22	2017-02-21	Genentech Inc	método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
EP2494066B1 (de) *	2009-10-27	2017-04-05	Swift Biosciences, Inc.	Bimolekulare primer
JP5866119B2 (ja)	2009-10-30	2016-02-17	ノースウェスタンユニバーシティ	鋳型ナノ複合体
US20130084565A1 (en)	2009-11-03	2013-04-04	University Of Virginia Patent Foundation	Versatile, visible method for detecting polymeric analytes
AR078921A1 (es) *	2009-11-09	2011-12-14	Hoffmann La Roche	Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
EP2504450B1 (de)	2009-11-23	2016-07-06	Swift Biosciences, Inc.	Vorrichtung zur erweiterung von einsträngigen zielmolekülen
PE20121584A1 (es)	2009-11-30	2012-11-29	Genentech Inc	Composiciones y metodos para el diagnostico y el tratamiento de tumores
WO2011084455A2 (en)	2009-12-16	2011-07-14	Opko Curna, Llc.	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
US20110152349A1 (en)	2009-12-18	2011-06-23	Anke Geick	Compositions and methods for inhibiting expression of il-18 genes
JP6031356B2 (ja)	2009-12-23	2016-11-24	カッパーアールエヌエー，インコーポレイテッド	Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
ES2661387T3 (es)	2009-12-23	2018-03-28	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
KR101838305B1 (ko)	2009-12-29	2018-03-13	큐알엔에이, 인크.	ＮＲＦ1(ＮｕｃｌｅａｒＲｅｓｐｉｒａｔｏｒｙＦａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
US8962585B2 (en)	2009-12-29	2015-02-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
EP2521784B1 (de)	2010-01-04	2017-12-06	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem interferonregulierungsfaktor 8 (irf8) mittels hemmung des natürlichen antisense-transkripts gegen irf8
CN102822342B (zh)	2010-01-06	2017-05-10	库尔纳公司	通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
US9200277B2 (en)	2010-01-11	2015-12-01	Curna, Inc.	Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2524042A2 (de)	2010-01-12	2012-11-21	Yale University	Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
CN102782135A (zh)	2010-01-25	2012-11-14	库尔纳公司	通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
CA2824843A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
TW201129365A (en)	2010-02-05	2011-09-01	Hoffmann La Roche	Compositions and methods for inhibiting expression of IKK2 genes
WO2011103528A2 (en)	2010-02-22	2011-08-25	Opko Curna Llc	Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
NZ601293A (en)	2010-02-23	2014-10-31	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
WO2011113054A2 (en)	2010-03-12	2011-09-15	Aurasense Llc	Crosslinked polynucleotide structure
WO2011112732A2 (en)	2010-03-12	2011-09-15	The Brigham And Women's Hospital, Inc.	Methods of treating vascular inflammatory disorders
WO2011115817A1 (en)	2010-03-16	2011-09-22	Isis Pharmaceuticals, Inc.	Methods of preparing 2'-o-substituted purine nucleosides
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011120046A2 (en)	2010-03-26	2011-09-29	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
CA2792291A1 (en)	2010-03-29	2011-10-06	Kumamoto University	Sirna therapy for transthyretin (ttr) related ocular amyloidosis
AU2011237630B2 (en)	2010-04-06	2016-01-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of CD274/PD-L1 gene
KR101900962B1 (ko)	2010-04-09	2018-09-20	큐알엔에이, 인크.	섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
WO2011133695A2 (en)	2010-04-20	2011-10-27	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US20130260460A1 (en)	2010-04-22	2013-10-03	Isis Pharmaceuticals Inc	Conformationally restricted dinucleotide monomers and oligonucleotides
EP3091027B1 (de)	2010-04-28	2018-01-17	Ionis Pharmaceuticals, Inc.	5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
EP2601204B1 (de)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modifizierte nukleoside und daraus hergestellte oligomere verbindungen
HRP20170737T1 (hr)	2010-04-29	2017-07-28	Ionis Pharmaceuticals, Inc.	Modulacija ekspresije transtiretina
US20130156845A1 (en)	2010-04-29	2013-06-20	Alnylam Pharmaceuticals, Inc.	Lipid formulated single stranded rna
CN102958941A (zh)	2010-05-03	2013-03-06	霍夫曼-拉罗奇有限公司	用于肿瘤诊断和治疗的组合物和方法
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CA2799207C (en)	2010-05-26	2019-03-26	Curna, Inc.	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
US20130203045A1 (en)	2010-05-26	2013-08-08	University Of Virginia Patent Foundation	Method for detecting nucleic acids based on aggregate formation
WO2011150227A1 (en)	2010-05-26	2011-12-01	Qiagen Gaithersburg, Inc.	Quantitative helicase assay
US9944671B2 (en)	2010-06-02	2018-04-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
WO2011156278A1 (en)	2010-06-07	2011-12-15	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
US9476101B2 (en)	2010-06-07	2016-10-25	Firefly Bioworks, Inc.	Scanning multifunctional particles
WO2011156202A1 (en)	2010-06-08	2011-12-15	Isis Pharmaceuticals, Inc.	Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9638632B2 (en)	2010-06-11	2017-05-02	Vanderbilt University	Multiplexed interferometric detection system and method
EP2582397A4 (de)	2010-06-15	2014-10-29	Isis Pharmaceuticals Inc	Verbindungen und verfahren zur modulierung der interaktion zwischen proteinen und zielnukleinsäuren
US9168297B2 (en)	2010-06-23	2015-10-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (NRG-1)
NO2593547T3 (de)	2010-07-14	2018-04-14
EP3489360A3 (de)	2010-07-19	2019-08-28	Ionis Pharmaceuticals, Inc.	Modulation einer kern-rna
WO2012021554A1 (en)	2010-08-09	2012-02-16	Yale University	Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
DK2620428T3 (da)	2010-09-24	2019-07-01	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
AU2011312205B2 (en)	2010-10-05	2015-08-13	Curis, Inc.	Mutant smoothened and methods of using the same
CA2813901C (en)	2010-10-06	2019-11-12	Curna, Inc.	Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
CN103517990A (zh)	2010-10-07	2014-01-15	通用医疗公司	癌症生物标志物
WO2012052258A1 (en)	2010-10-18	2012-04-26	Arrowhead Research Corporation	Compositions and methods for inhibiting expression of rrm2 genes
US8648053B2 (en)	2010-10-20	2014-02-11	Rosalind Franklin University Of Medicine And Science	Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
JP6049623B2 (ja)	2010-10-22	2016-12-21	カッパーアールエヌエー，インコーポレイテッド	α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
CA2816056A1 (en)	2010-10-27	2012-05-03	Curna, Inc.	Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
CN110123830A (zh)	2010-11-09	2019-08-16	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
AU2011325956B2 (en)	2010-11-12	2016-07-14	The General Hospital Corporation	Polycomb-associated non-coding RNAs
WO2012068405A2 (en)	2010-11-17	2012-05-24	Isis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
WO2012071238A2 (en)	2010-11-23	2012-05-31	Opko Curna Llc	Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
US9193973B2 (en)	2010-12-10	2015-11-24	Alynylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (EPO) production
EP2648763A4 (de)	2010-12-10	2014-05-14	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
EP2663323B1 (de)	2011-01-14	2017-08-16	The General Hospital Corporation	Verfahren zur anzielung von mir-128 zur regelung des cholesterin-/fettstoffwechsels
SI2670411T1 (sl)	2011-02-02	2019-06-28	Excaliard Pharmaceuticals, Inc.	Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
DK2670404T3 (en)	2011-02-02	2018-11-19	Univ Princeton	CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
EP3369828B1 (de)	2011-02-07	2020-07-15	The Governing Council Of The University Of Toronto	Biosonden und verfahren zur verwendung davon
EP3067421B1 (de)	2011-02-08	2018-10-10	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
MX360349B (es)	2011-03-29	2018-10-30	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
JP2014511694A (ja)	2011-04-03	2014-05-19	ザジェネラルホスピタルコーポレーションドゥーイングビジネスアズマサチューセッツジェネラルホスピタル	修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現
WO2012149154A1 (en)	2011-04-26	2012-11-01	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
WO2012151324A1 (en)	2011-05-02	2012-11-08	Isis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
RU2620980C2 (ru)	2011-06-09	2017-05-30	Курна, Инк.	Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
KR20230084331A (ko)	2011-06-21	2023-06-12	알닐람 파마슈티칼스 인코포레이티드	아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
EP3444348A1 (de)	2011-06-21	2019-02-20	Alnylam Pharmaceuticals, Inc.	Angiopoietin-3 (angptl3)-irna-zusammensetzungen und verfahren zur verwendung davon
EP3388068A1 (de)	2011-06-21	2018-10-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
WO2012178033A2 (en)	2011-06-23	2012-12-27	Alnylam Pharmaceuticals, Inc.	Serpina1 sirnas: compositions of matter and methods of treatment
US9222093B2 (en)	2011-06-30	2015-12-29	The University Of Hong Kong	Two-way, portable riboswitch mediated gene expression control device
JP6165723B2 (ja)	2011-06-30	2017-07-19	アローヘッドファーマシューティカルズインコーポレイテッド	Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
US9605019B2 (en)	2011-07-19	2017-03-28	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
WO2013019857A2 (en)	2011-08-01	2013-02-07	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
US10202599B2 (en)	2011-08-11	2019-02-12	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
EP3640332A1 (de)	2011-08-29	2020-04-22	Ionis Pharmaceuticals, Inc.	Oligomer-konjugat-komplexe und deren verwendung
EP2751269B1 (de)	2011-08-29	2016-03-23	Ionis Pharmaceuticals, Inc.	Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion
JP2014526517A (ja)	2011-09-14	2014-10-06	ノースウェスタンユニバーシティ	血液脳関門を通過することができるナノ抱合体
JP6129844B2 (ja)	2011-09-14	2017-05-17	ラナセラピューティクスインコーポレイテッド	多量体オリゴヌクレオチド化合物
US9580713B2 (en)	2011-09-17	2017-02-28	Yale University	Fluoride-responsive riboswitches, fluoride transporters, and methods of use
EP2766482B1 (de)	2011-10-11	2016-12-07	The Brigham and Women's Hospital, Inc.	Mikro-rnas in neurodegenerativen erkrankungen
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
US9243291B1 (en)	2011-12-01	2016-01-26	Isis Pharmaceuticals, Inc.	Methods of predicting toxicity
WO2013090457A2 (en)	2011-12-12	2013-06-20	Oncoimmunin Inc.	In vivo delivery of oligonucleotides
SG10201610936RA (en)	2011-12-22	2017-02-27	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
WO2013106770A1 (en)	2012-01-11	2013-07-18	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of ikbkap splicing
CN108300765B (zh)	2012-03-13	2022-01-11	斯威夫特生物科学公司	用于通过核酸聚合酶对衬底多核苷酸进行大小受控的同聚物加尾的方法和组合物
EP2825648B1 (de)	2012-03-15	2018-09-05	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
WO2013138662A1 (en)	2012-03-16	2013-09-19	4S3 Bioscience, Inc.	Antisense conjugates for decreasing expression of dmpk
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
WO2013148283A1 (en)	2012-03-30	2013-10-03	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
EP2850092B1 (de)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclische nukleinsäureanaloga
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
EP2839006B1 (de)	2012-04-20	2018-01-03	Ionis Pharmaceuticals, Inc.	Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
CN104704122A (zh)	2012-04-20	2015-06-10	艾珀特玛治疗公司	产热的miRNA调节剂
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
WO2013163628A2 (en)	2012-04-27	2013-10-31	Duke University	Genetic correction of mutated genes
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
KR20150030205A (ko)	2012-05-16	2015-03-19	라나 테라퓨틱스, 인크.	Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
CN104583398A (zh)	2012-05-16	2015-04-29	Rana医疗有限公司	用于调节基因表达的组合物和方法
US9574193B2 (en)	2012-05-17	2017-02-21	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein (a) expression
WO2013173789A2 (en)	2012-05-17	2013-11-21	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide compositions
US9828602B2 (en)	2012-06-01	2017-11-28	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
US9487780B2 (en)	2012-06-01	2016-11-08	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
US20130330389A1 (en)	2012-06-08	2013-12-12	The Regents Of The University Of Michigan	Ultrasound-triggerable agents for tissue engineering
CN112007045B (zh)	2012-07-13	2026-01-06	波涛生命科学有限公司	手性控制
JP6246121B2 (ja)	2012-07-13	2017-12-13	株式会社新日本科学	キラル核酸アジュバント
DK2872485T3 (da)	2012-07-13	2021-03-08	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
CA2880833A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US9403865B2 (en)	2012-08-15	2016-08-02	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
EP2892617B1 (de)	2012-09-06	2018-06-13	The University of Chicago	Antisense-polynukleotide zur induktion von exon-skipping sowie verfahren zur behandlung von muskeldystrophien
WO2014059353A2 (en)	2012-10-11	2014-04-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
US20150275208A1 (en)	2012-10-12	2015-10-01	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
WO2014059341A2 (en)	2012-10-12	2014-04-17	Isis Pharmaceuticals, Inc.	Antisense compounds and uses thereof
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2887702C (en)	2012-10-26	2023-08-01	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
WO2014071419A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
WO2014093537A1 (en)	2012-12-11	2014-06-19	Isis Pharmaceuticals, Inc.	Competitive modulation of micrornas
WO2014113729A2 (en)	2013-01-18	2014-07-24	Foundation Mecicine, Inc.	Methods of treating cholangiocarcinoma
US10260069B2 (en)	2013-02-04	2019-04-16	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
JP2016519083A (ja)	2013-03-14	2016-06-30	アンデスバイオテクノロジーズソシエダードアノニマＡｎｄｅｓＢｉｏｔｅｃｈｎｏｌｏｇｉｅｓＳ．Ａ．	多発性骨髄腫を検出および処置するための方法
CN111254145A (zh)	2013-03-14	2020-06-09	Ionis制药公司	用于调节tau表达的组合物和方法
HUE042738T2 (hu)	2013-03-14	2019-07-29	Andes Biotechnologies Global Inc	Antiszensz oligonukleotidok rákos õssejtek kezelésére
ME03043B (de)	2013-03-14	2018-10-20	Alnylam Pharmaceuticals Inc	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
US9347095B2 (en)	2013-03-15	2016-05-24	Bio-Rad Laboratories, Inc.	Digital assays for mutation detection
US9828582B2 (en)	2013-03-19	2017-11-28	Duke University	Compositions and methods for the induction and tuning of gene expression
US9937231B2 (en)	2013-03-27	2018-04-10	The General Hospital Corporation	Methods and agents for treating Alzheimer's disease
JP2016522679A (ja)	2013-04-04	2016-08-04	プレジデントアンドフェローズオブハーバードカレッジ	ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
US9677075B2 (en)	2013-04-23	2017-06-13	Northwestern University	Metal-ligand coordination polymer nanoparticles and methods for making
CA2921162A1 (en)	2013-05-01	2014-11-06	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
KR102463973B1 (ko)	2013-05-22	2022-11-07	알닐람 파마슈티칼스 인코포레이티드	ＳＥＲＰＩＮＡ1 ｉＲＮＡ 조성물 및 이의 사용 방법
EA201592225A1 (ru)	2013-05-22	2016-04-29	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014197835A2 (en)	2013-06-06	2014-12-11	The General Hospital Corporation	Methods and compositions for the treatment of cancer
EP3007704B1 (de)	2013-06-13	2021-01-06	Antisense Therapeutics Ltd	Kombinationstherapie der akromegalie
JP6694382B2 (ja)	2013-06-21	2020-05-13	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	標的核酸を調節するための組成物および方法
JP6617702B2 (ja)	2013-07-15	2019-12-11	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｆｔｙ７２０のアザサイクリック拘束アナログ
TWI657819B (zh)	2013-07-19	2019-05-01	美商Ionis製藥公司	用於調節τ蛋白表現之組合物
KR20160042917A (ko)	2013-07-25	2016-04-20	엑시큐어, 인크.	예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
WO2015017675A2 (en)	2013-07-31	2015-02-05	Isis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
RS59991B1 (sr)	2013-08-08	2020-04-30	Scripps Research Inst	Metoda enzimskog in vitro obeležavanja specifičnog za položaj nukleinskih kiselina uvođenjem neprirodnih nukleotida
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
US9943604B2 (en)	2013-09-20	2018-04-17	Ionis Pharmaceuticals, Inc.	Targeted therapeutic nucleosides and their use
CA2925107A1 (en)	2013-10-02	2015-04-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
EP3052627B1 (de)	2013-10-04	2018-08-22	Novartis AG	Neuartige formate für organische verbindungen zur verwendung bei rna-interferenz
SG11201602631XA (en)	2013-10-04	2016-05-30	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of the alas1 gene
JP6546161B2 (ja)	2013-10-04	2019-07-17	ノバルティスアーゲー	Ｂ型肝炎ウイルスを治療するための有機化合物
KR102298475B1 (ko)	2013-10-04	2021-09-06	노파르티스 아게	ＲＮＡ 간섭에 사용하기 위한 ＲＮＡｉ 작용제를 위한 3' 말단 캡
WO2015054451A1 (en)	2013-10-09	2015-04-16	The United States Of America As Represented By The Secretary Department Of Health And Human Services	Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
EP3060680B1 (de)	2013-10-21	2019-02-27	The General Hospital Corporation	Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und krebsbehandlung
WO2015066708A1 (en)	2013-11-04	2015-05-07	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
US10752940B2 (en)	2013-11-08	2020-08-25	Ionis Pharmaceuticals, Inc.	Compounds and methods for detecting oligonucleotides
EP3077510B1 (de)	2013-12-02	2020-05-06	Ionis Pharmaceuticals, Inc.	Antisense-verbindungen und verwendungen davon
JP6527516B2 (ja)	2013-12-03	2019-06-05	ノースウェスタンユニバーシティ	リポソーム粒子、前述のものを作製する方法及びその使用
WO2015085183A2 (en)	2013-12-06	2015-06-11	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
CA2931090A1 (en)	2013-12-12	2015-06-18	Alnylam Pharmaceuticals, Inc.	Complement component irna compositions and methods of use thereof
AU2014364520B2 (en)	2013-12-20	2020-01-02	The General Hospital Corporation	Methods and assays relating to circulating tumor cells
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en)	2014-01-15	2019-06-18	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (de)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
KR102423317B1 (ko)	2014-01-16	2022-07-22	웨이브 라이프 사이언시스 리미티드	키랄 디자인
ES2694857T3 (es)	2014-02-04	2018-12-27	Genentech, Inc.	Smoothened mutante y métodos de uso de la misma
AU2015217301A1 (en)	2014-02-11	2016-08-25	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (KHK) iRNA compositions and methods of use thereof
WO2015142910A1 (en)	2014-03-17	2015-09-24	Isis Pharmaceuticals, Inc.	Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
WO2015143245A1 (en)	2014-03-19	2015-09-24	Isis Pharmaceuticals, Inc.	Methods for modulating ataxin 2 expression
CN116970607A (zh)	2014-03-19	2023-10-31	Ionis制药公司	用于调节共济失调蛋白2表达的组合物
MY192634A (en)	2014-04-01	2022-08-29	Biogen Ma Inc	Compositions for modulating sod-1 expression
TWI638047B (zh)	2014-04-09	2018-10-11	史基普研究協會	藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
US10221416B2 (en)	2014-04-24	2019-03-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015168172A1 (en)	2014-04-28	2015-11-05	Isis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds
US10280423B2 (en)	2014-05-01	2019-05-07	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating complement factor B expression
MX382230B (es)	2014-05-01	2025-03-13	Ionis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
AU2015252841B2 (en)	2014-05-01	2020-03-19	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating growth hormone receptor expression
WO2015175510A1 (en)	2014-05-12	2015-11-19	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating a serpinc1-associated disorder
BR122020023687B1 (pt)	2014-05-22	2023-03-07	Alnylam Pharmaceuticals, Inc	Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
US10570169B2 (en)	2014-05-22	2020-02-25	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
CN106659758A (zh)	2014-06-02	2017-05-10	儿童医疗中心有限公司	用于免疫调节的组合物和方法
EP3164113B1 (de)	2014-06-04	2019-03-27	Exicure, Inc.	Multivalente freisetzung von immunmodulatoren durch liposomale sphärische nukleinsäuren für prophylaktische oder therapeutische anwendungen
WO2015190922A1 (en)	2014-06-10	2015-12-17	Erasmus University Medical Center Rotterdam	Antisense oligonucleotides useful in treatment of pompe disease
TW201620526A (zh)	2014-06-17	2016-06-16	愛羅海德研究公司	用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
EP3760208B1 (de)	2014-06-25	2024-05-29	The General Hospital Corporation	Targeting von humanem satellit ii (hsatii)
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
CA2954475C (en)	2014-07-31	2023-05-16	Uab Research Foundation	Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2016028940A1 (en)	2014-08-19	2016-02-25	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
US9617541B2 (en)	2014-08-20	2017-04-11	Northwestern University	Biocompatible infinite coordination polymer nanoparticle-nucleic acid conjugates for antisense gene regulation
EP4137138A1 (de)	2014-08-29	2023-02-22	Alnylam Pharmaceuticals, Inc.	Verfahren zum behandeln von transthyretin (ttr)-vermittelter amyloidose
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
ES2985036T3 (es)	2014-08-29	2024-11-04	Childrens Medical Ct Corp	Métodos y composiciones para el tratamiento del cáncer
WO2016040748A1 (en)	2014-09-12	2016-03-17	Ionis Pharmaceuticals, Inc.	Compositions and methods for detection of smn protein in a subject and treatment of a subject
EP3191591A1 (de)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
EP3198012B1 (de)	2014-09-26	2019-09-04	University of Massachusetts	Rna-modulierende stoffe
TWI864340B (zh)	2014-10-10	2024-12-01	美商艾爾妮蘭製藥公司	用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
EP3207138B1 (de)	2014-10-17	2020-07-15	Alnylam Pharmaceuticals, Inc.	Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
EP3904519A1 (de)	2014-10-30	2021-11-03	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
SG11201703638XA (en)	2014-11-10	2017-06-29	Alnylam Pharmaceuticals Inc	Hepatitis b virus (hbv) irna compositions and methods of use thereof
WO2016077540A1 (en)	2014-11-12	2016-05-19	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of comp
AU2015346042A1 (en)	2014-11-14	2017-04-27	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of proteins
CA2968114A1 (en)	2014-11-17	2016-05-26	Alnylam Pharmaceuticals, Inc.	Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3229842B1 (de)	2014-12-08	2022-07-06	The Board of Regents of The University of Texas System	Lipokationische polymere und verwendungen davon
US12359197B2 (en)	2014-12-12	2025-07-15	Etagen Pharma, Inc.	Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en)	2015-01-06	2016-07-14	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
WO2016115490A1 (en)	2015-01-16	2016-07-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of dux4
WO2016118812A1 (en)	2015-01-23	2016-07-28	Vanderbilt University	A robust interferometer and methods of using same
JP6929791B2 (ja)	2015-02-09	2021-09-01	デュークユニバーシティ	エピゲノム編集のための組成物および方法
WO2016130806A2 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3262173A2 (de)	2015-02-23	2018-01-03	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von humangenetischen erkrankungen einschliesslich hämoglobinopathien
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
AU2016243583B2 (en)	2015-03-27	2022-03-10	President And Fellows Of Harvard College	Modified T cells and methods of making and using the same
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
PT3283500T (pt)	2015-04-08	2021-01-28	Univ Chicago	Composições e métodos para corrigir distrofia muscular das cinturas tipo 2c com utilização de salto do exão
MX2017012610A (es)	2015-04-08	2018-03-16	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen lect2.
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
WO2016201301A1 (en)	2015-06-12	2016-12-15	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (de)	2015-06-18	2020-08-05	Alnylam Pharmaceuticals, Inc.	Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
CA2990852A1 (en)	2015-06-26	2016-12-29	Beth Israel Deaconess Medical Center, Inc.	Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
CA2990699A1 (en)	2015-06-29	2017-01-05	Ionis Pharmaceuticals, Inc.	Modified crispr rna and modified single crispr rna and uses thereof
IL318703A (en)	2015-06-29	2025-03-01	Caris Science Inc	Therapeutic oligonucleotides
PE20180800A1 (es)	2015-07-10	2018-05-09	Ionis Pharmaceuticals Inc	Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
US10494632B2 (en)	2015-07-10	2019-12-03	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
WO2017015575A1 (en)	2015-07-22	2017-01-26	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
EP3328873B1 (de)	2015-07-28	2025-09-17	Caris Science, Inc.	Gezielte oligonukleotide
EP3332009A1 (de)	2015-08-04	2018-06-13	Yeda Research and Development Co., Ltd.	Verfahren zum screening auf riboswitches und attenuatoren
KR20180038465A (ko)	2015-08-07	2018-04-16	애로우헤드 파마슈티컬스 인코포레이티드	Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
CN108368507B (zh)	2015-09-02	2022-03-22	阿尔尼拉姆医药品有限公司	程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
CN108271360B (zh)	2015-09-14	2023-01-24	得克萨斯州大学系统董事会	亲脂阳离子树枝状聚合物及其用途
CN108366990B (zh)	2015-09-24	2021-09-03	加利福尼亚大学董事会	合成的鞘脂类分子、药物、它们的合成方法及治疗方法
HK1255699A1 (zh)	2015-09-24	2019-08-23	Ionis Pharmaceuticals, Inc.	Kras表达的调节剂
CA2998287A1 (en)	2015-09-24	2017-04-20	Crispr Therapeutics Ag	Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
US10533175B2 (en)	2015-09-25	2020-01-14	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating Ataxin 3 expression
US10709812B2 (en)	2015-09-29	2020-07-14	The Regents Of The University Of Michigan	Biodegradable hydrogel for tissue expansion
EP4089175A1 (de)	2015-10-13	2022-11-16	Duke University	Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
AU2016344609B2 (en)	2015-10-28	2022-05-12	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of duchenne muscular dystrophy
ES2938883T3 (es)	2015-11-05	2023-04-17	Los Angeles Childrens Hospital	Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
SI4119569T1 (sl)	2015-11-06	2024-10-30	Ionis Pharmaceuticals, Inc.	Konjugirane protismiselne spojine za uporabo v terapiji
EP3371305A1 (de)	2015-11-06	2018-09-12	Crispr Therapeutics AG	Materialien und verfahren zur behandlung der glycogenspeicherkrankheit des typs 1a
EP3370708A4 (de)	2015-11-06	2019-06-26	Ionis Pharmaceuticals, Inc.	Modulation der apolipoprotein (a)-expression
CA3005878A1 (en)	2015-11-19	2017-05-26	The Brigham And Women's Hospital, Inc.	Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017095967A2 (en)	2015-11-30	2017-06-08	Duke University	Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
AU2016364667A1 (en)	2015-12-01	2018-06-21	Crispr Therapeutics Ag	Materials and methods for treatment of Alpha-1 antitrypsin deficiency
US11058709B1 (en)	2015-12-04	2021-07-13	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
CA3007152A1 (en)	2015-12-07	2017-06-15	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for pompe disease
SG11201804729RA (en)	2015-12-07	2018-07-30	Genzyme Corp	Methods and compositions for treating a serpinc1-associated disorder
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
MX2018007840A (es)	2015-12-23	2019-05-02	Crispr Therapeutics Ag	Materiales y metodos para el tratamiento de la esclerosis lateral amiotrofica y/o la degeneracion lobar frontotemporal.
CA3006015A1 (en)	2015-12-31	2017-07-06	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
AU2017205462A1 (en)	2016-01-05	2018-06-07	Ionis Pharmaceuticals, Inc.	Methods for reducing LRRK2 expression
US10627396B2 (en)	2016-01-29	2020-04-21	Vanderbilt University	Free-solution response function interferometry
WO2017134529A1 (en)	2016-02-02	2017-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
AU2017213826A1 (en)	2016-02-04	2018-08-23	Curis, Inc.	Mutant smoothened and methods of using the same
WO2017141109A1 (en)	2016-02-18	2017-08-24	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
JP7033072B2 (ja)	2016-02-25	2022-03-09	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	Ｓｍｏｃ２を標的化する線維症のための治療方法
CA3016592A1 (en)	2016-03-04	2017-09-08	Rhode Island Hospital	Targeting microrna for cancer treatment
US11136577B2 (en)	2016-03-09	2021-10-05	Ionis Pharmaceuticals, Inc.	Methods and compositions for inhibiting PMP22 expression
WO2017158422A1 (en)	2016-03-16	2017-09-21	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
EP3429690A4 (de)	2016-03-16	2019-10-23	Ionis Pharmaceuticals, Inc.	Verfahren zur modulation von keap1
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
WO2017161357A1 (en)	2016-03-18	2017-09-21	Caris Science, Inc.	Oligonucleotide probes and uses thereof
ES2933435T3 (es)	2016-04-13	2023-02-08	Ionis Pharmaceuticals Inc	Métodos para reducir la expresión de C9ORF72
EP3443081A4 (de)	2016-04-13	2019-10-30	Duke University	Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
JP6974349B2 (ja)	2016-04-18	2021-12-01	クリスパーセラピューティクスアクチェンゲゼルシャフト	ヘモグロビン異常症の処置のための材料及び方法
WO2017184689A1 (en)	2016-04-19	2017-10-26	Alnylam Pharmaceuticals, Inc.	High density lipoprotein binding protein (hdlbp/vigilin) irna compositions and methods of use thereof
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
KR102706686B1 (ko)	2016-05-06	2024-09-19	아이오니스 파마수티컬즈, 인코포레이티드	Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
AU2017267634C1 (en)	2016-05-16	2022-05-26	The Board Of Regents Of The University Of Texas System	Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
CA3025486A1 (en)	2016-05-25	2017-11-30	Caris Science, Inc.	Oligonucleotide probes and uses thereof
WO2017214518A1 (en)	2016-06-10	2017-12-14	Alnylam Pharmaceuticals, Inc.	COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
EP3472350B1 (de)	2016-06-15	2022-08-17	Streck, Inc.	Test und verfahren zu bestimmung mikrobieller resistenz
CA3023514A1 (en)	2016-06-17	2017-12-21	Ionis Pharmaceuticals, Inc.	Modulation of gys1 expression
EP4163293A1 (de)	2016-06-24	2023-04-12	The Scripps Research Institute	Neuartiger nukleosid-triphosphat-transporter und verwendungen davon
US11174469B2 (en)	2016-06-29	2021-11-16	Crispr Therapeutics Ag	Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
US11564997B2 (en)	2016-06-29	2023-01-31	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
WO2018002812A1 (en)	2016-06-29	2018-01-04	Crispr Therapeutics Ag	Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
CA3029132A1 (en)	2016-07-06	2018-01-11	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
US11459587B2 (en)	2016-07-06	2022-10-04	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
AU2017296195A1 (en)	2016-07-11	2019-01-24	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
ES2935658T3 (es)	2016-07-15	2023-03-09	Ionis Pharmaceuticals Inc	Compuestos y métodos para la modulación de SMN2
EP4275747A3 (de)	2016-07-19	2024-01-24	Duke University	Therapeutische anwendungen von cpf1-basierter genomeditierung
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
JOP20190015A1 (ar)	2016-08-04	2019-02-04	Arrowhead Pharmaceuticals Inc	عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018035380A1 (en)	2016-08-17	2018-02-22	Solstice Biologics, Ltd.	Polynucleotide constructs
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
SG10201607303YA (en)	2016-09-01	2018-04-27	Agency Science Tech & Res	Antisense oligonucleotides to induce exon skipping
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
ES2963428T3 (es)	2016-09-29	2024-03-27	Biogen Ma Inc	Compuestos y métodos para reducir la expresión de Tau
KR20190065341A (ko)	2016-10-06	2019-06-11	아이오니스 파마수티컬즈, 인코포레이티드	올리고머 화합물들의 접합 방법
SG10201609048RA (en)	2016-10-28	2018-05-30	Agency Science Tech & Res	Antisense oligonucleotides
CA3037046A1 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
TW202313978A (zh)	2016-11-23	2023-04-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
US11033570B2 (en)	2016-12-02	2021-06-15	Cold Spring Harbor Laboratory	Modulation of Lnc05 expression
CN118546256A (zh)	2016-12-13	2024-08-27	西雅图儿童医院（Dba西雅图儿童研究所）	在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
AU2017376950B2 (en)	2016-12-16	2024-02-22	Alnylam Pharmaceuticals, Inc.	Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
UY37565A (es)	2017-01-10	2018-07-31	Arrowhead Pharmaceuticals Inc	Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso
SG11201906735RA (en)	2017-01-23	2019-08-27	Regeneron Pharma	Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
EP3585807A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung der parkinson-krankheit im frühstadium (park1) und anderer zustände oder störungen im zusammenhang mit dem synuclein-alpha (snca)-gen
CN119351474A (zh)	2017-02-22	2025-01-24	克里斯珀医疗股份公司	用于基因编辑的组合物和方法
EP3585899A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
US20200216857A1 (en)	2017-02-22	2020-07-09	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
EP3585898A1 (de)	2017-02-22	2020-01-01	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von spinozerebellärer ataxie typ 1 (sca1) und anderen mit dem gen des proteins von spinozerebellärer ataxie typ 1 (atxn1) assoziierten erkrankungen oder störungen
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
JOP20190215A1 (ar)	2017-03-24	2019-09-19	Ionis Pharmaceuticals Inc	مُعدّلات التعبير الوراثي عن pcsk9
WO2018183969A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
WO2018191603A1 (en)	2017-04-14	2018-10-18	University Of Massachusetts	Targeting cell tropism receptors to inhibit cytomegalovirus infection
KR102808275B1 (ko)	2017-04-14	2025-05-20	탈락 테라퓨틱스, 인크.	면역조절 폴리뉴클레오티드, 이의 항체 접합체, 및 이의 사용 방법
SG11201909572QA (en)	2017-04-18	2019-11-28	Alnylam Pharmaceuticals Inc	Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
CA3059321A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
WO2018193428A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
US12208140B2 (en)	2017-04-21	2025-01-28	The Broad Institute, Inc.	Targeted delivery to beta cells
WO2018209270A1 (en)	2017-05-11	2018-11-15	Northwestern University	Adoptive cell therapy using spherical nucleic acids (snas)
BR112019023608A2 (pt)	2017-05-12	2020-05-26	Crispr Therapeutics Ag	Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
WO2019006455A1 (en)	2017-06-30	2019-01-03	Solstice Biologics, Ltd.	AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
JP2020530442A (ja)	2017-07-10	2020-10-22	ジェンザイム・コーポレーション	血友病を有する対象の出血事象を処置するための方法および組成物
SG11202000167SA (en)	2017-07-11	2020-02-27	Synthorx Inc	Incorporation of unnatural nucleotides and methods thereof
CA3069868A1 (en)	2017-07-13	2019-01-17	Alnylam Pharmaceuticals Inc.	Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
JP2020526558A (ja)	2017-07-13	2020-08-31	ノースウェスタンユニバーシティ	オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
KR20250145137A (ko)	2017-08-03	2025-10-13	신톡스, 인크.	자가면역 질환의 치료를 위한 사이토카인 접합체
AU2018318231A1 (en)	2017-08-18	2020-02-13	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
US10517889B2 (en)	2017-09-08	2019-12-31	Ionis Pharmaceuticals, Inc.	Modulators of SMAD7 expression
US11999953B2 (en)	2017-09-13	2024-06-04	The Children's Medical Center Corporation	Compositions and methods for treating transposon associated diseases
KR20200089656A (ko)	2017-09-19	2020-07-27	알닐람 파마슈티칼스 인코포레이티드	트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
WO2019079527A1 (en)	2017-10-17	2019-04-25	Casebia Therapeutics Limited Liability Partnership	COMPOSITIONS AND METHODS FOR GENETIC EDITION FOR HEMOPHILIA A
EP3701029A1 (de)	2017-10-26	2020-09-02	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
US11866701B2 (en)	2017-11-01	2024-01-09	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US20210032622A1 (en)	2017-11-09	2021-02-04	Crispr Therapeutics Ag	Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
US20200385719A1 (en)	2017-11-16	2020-12-10	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
EP3714054A1 (de)	2017-11-20	2020-09-30	Alnylam Pharmaceuticals, Inc.	Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
WO2019102381A1 (en)	2017-11-21	2019-05-31	Casebia Therapeutics Llp	Materials and methods for treatment of autosomal dominant retinitis pigmentosa
SG11202005147WA (en)	2017-12-05	2020-06-29	Vertex Pharma	Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
CN111801417B (zh)	2017-12-14	2024-10-29	克里斯珀医疗股份公司	新的rna-可编程的内切核酸酶系统及其在基因组编辑和其他应用中的用途
EP3724206B1 (de)	2017-12-14	2023-06-28	Ionis Pharmaceuticals, Inc.	Konjugierte antisense-verbindungen und deren verwendung
WO2019126097A1 (en)	2017-12-18	2019-06-27	Alnylam Pharmaceuticals, Inc.	High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
EP3728595A1 (de)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
EP3728594A1 (de)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung des usher-syndroms typ 2a
IL275694B2 (en)	2017-12-29	2025-08-01	Scripps Research Inst	Unnatural base pair compositions and methods of use
US12178855B2 (en)	2018-01-10	2024-12-31	Translate Bio Ma, Inc.	Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
WO2019140330A1 (en)	2018-01-12	2019-07-18	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for gene editing by targeting transferrin
US20200392510A1 (en)	2018-01-15	2020-12-17	Ionis Pharmaceuticals, Inc.	Modulators of dnm2 expression
US12509492B2 (en)	2018-01-19	2025-12-30	Duke University	Genome engineering with CRISPR-Cas systems in eukaryotes
WO2019142135A1 (en)	2018-01-19	2019-07-25	Synthena Ag	Tricyclo-dna nucleoside precursors and processes for preparing the same
WO2019147743A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
US11268077B2 (en)	2018-02-05	2022-03-08	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
WO2019150196A1 (en)	2018-02-05	2019-08-08	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
CA3090901A1 (en)	2018-02-12	2019-08-15	Ionis Pharmaceuticals, Inc.	Modified compounds and uses thereof
WO2019161310A1 (en)	2018-02-16	2019-08-22	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for gene editing by targeting fibrinogen-alpha
WO2019165453A1 (en)	2018-02-26	2019-08-29	Synthorx, Inc.	Il-15 conjugates and uses thereof
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
US11732260B2 (en)	2018-03-02	2023-08-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-β precursor protein
JP7550648B2 (ja)	2018-03-19	2024-09-13	クリスパーセラピューティクスアーゲー	新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
EP3768694A4 (de)	2018-03-22	2021-12-29	Ionis Pharmaceuticals, Inc.	Verfahren zur modulierung der fmr1-expression
AU2019242912B2 (en)	2018-03-28	2025-07-17	Board Of Regents, The University Of Texas System	Identification of epigenetic alterations in DNA isolated from exosomes
WO2019186514A2 (en)	2018-03-30	2019-10-03	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activaton of t cell-mediated immunity
CN116536272A (zh)	2018-04-06	2023-08-04	儿童医疗中心有限公司	用于体细胞重新编程和调整印记的组合物和方法
CA3094020A1 (en)	2018-04-11	2019-10-17	Ionis Pharmaceuticals, Inc.	Modulators of ezh2 expression
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
CA3091490A1 (en)	2018-04-27	2019-10-31	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Rapamycin resistant cells
US12263205B2 (en)	2018-04-30	2025-04-01	The Children's Hospital Of Philadelphia	Methods of improving anemias by combining agents
US20210172928A1 (en)	2018-05-03	2021-06-10	The Trustees Of Wheaton College	Improved membranes for nanopore sensing applications
SG11202010215TA (en)	2018-05-09	2020-11-27	Ionis Pharmaceuticals Inc	Compounds and methods for reducing atxn3 expression
JP7438135B2 (ja)	2018-05-09	2024-02-26	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｆｘｉの発現を低下させるための化合物及び方法
CA3099963A1 (en)	2018-05-11	2019-11-14	University Of Massachusetts	Methods for improving leptin sensitivity for the treatment of obesity and diabetes
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
US11833168B2 (en)	2018-06-14	2023-12-05	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing STMN2 expression
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
EP3823725A4 (de)	2018-07-17	2023-05-10	Aronora, Inc.	Verfahren zur sicheren reduzierung von thrombopoietin
CA3106986A1 (en)	2018-07-25	2020-01-30	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing atxn2 expression
MA70658B1 (fr)	2018-08-13	2026-04-30	Alnylam Pharmaceuticals, Inc.	Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation
US11987792B2 (en)	2018-08-16	2024-05-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
CA3110211A1 (en)	2018-08-20	2020-02-27	Rogcon, Inc.	Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies
US12281308B2 (en)	2018-08-29	2025-04-22	University Of Massachusetts	Inhibition of protein kinases to treat Friedreich ataxia
EP3620520A1 (de)	2018-09-10	2020-03-11	Universidad del Pais Vasco	Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
CA3112793A1 (en)	2018-09-14	2020-03-19	Northwestern University	Programming protein polymerization with dna
WO2020060986A1 (en)	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
TWI869213B (zh)	2018-09-19	2025-01-01	美商Ionis製藥公司	Pnpla3表現之調節劑
WO2020068983A1 (en)	2018-09-25	2020-04-02	Co-Diagnostics, Inc.	Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
CA3116885A1 (en)	2018-10-17	2020-04-23	Crispr Therapeutics Ag	Compositions and methods for delivering transgenes
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
BR112021005401A2 (pt)	2018-11-08	2021-06-29	Synthorx, Inc.	conjugados de interleucina 10 e usos dos mesmos
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
EA202191342A1 (ru)	2018-11-15	2021-08-10	Айонис Фармасьютикалз, Инк.	Модуляторы экспрессии irf5
US12281305B2 (en)	2018-11-21	2025-04-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing prion expression
CA3121191A1 (en)	2018-11-28	2020-06-04	Crispr Therapeutics Ag	Optimized mrna encoding cas9 for use in lnps
WO2020117706A1 (en)	2018-12-03	2020-06-11	Triplet Therapeutics, Inc.	Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
WO2020118259A1 (en)	2018-12-06	2020-06-11	Northwestern University	Protein crystal engineering through dna hybridization interactions
CN113631709A (zh)	2018-12-20	2021-11-09	普拉克西斯精密药物股份有限公司	用于治疗kcnt1相关病症的组合物和方法
LT4285929T (lt)	2018-12-20	2026-01-12	Humabs Biomed Sa	Kompleksinė hbv terapija
US20220273691A1 (en)	2018-12-21	2022-09-01	Ionis Pharmaceuticals, Inc.	Modulators of hsd17b13 expression
WO2020132647A1 (en)	2018-12-21	2020-06-25	Northwestern University	Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en)	2018-12-26	2020-07-02	Northwestern University	Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
CN113557023A (zh)	2019-01-16	2021-10-26	建新公司	Serpinc1 iRNA组合物及其使用方法
MX2021008918A (es)	2019-01-31	2021-08-24	Ionis Pharmaceuticals Inc	Moduladores de expresion yap1.
US20200246467A1 (en)	2019-02-06	2020-08-06	Synthorx, Inc.	Il-2 conjugates and methods of use thereof
EP3923992A1 (de)	2019-02-15	2021-12-22	CRISPR Therapeutics AG	Geneditierung für hämophilie a mit verbesserter faktor-viii-expression
WO2020176771A1 (en)	2019-02-27	2020-09-03	Ionis Pharmaceuticals, Inc.	Modulators of malat1 expression
US20220175956A1 (en)	2019-03-06	2022-06-09	Northwestern University	Hairpin-like oligonucleotide-conjugated spherical nucleic acid
WO2020185781A1 (en)	2019-03-11	2020-09-17	Ochsner Health System	Microrna regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage
US20220145274A1 (en)	2019-03-12	2022-05-12	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
CA3135180A1 (en)	2019-03-29	2020-10-08	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating ube3a-ats
TWI902693B (zh)	2019-05-13	2025-11-01	美商維爾生物科技公司	用於治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物及方法
SI3976791T1 (sl)	2019-05-28	2025-06-30	Ionis Pharmaceuticals, Inc.	Spojine in postopki za zmanjševanje izražanja fus
WO2020243644A1 (en)	2019-05-31	2020-12-03	Streck, Inc.	Detection of antibiotic resistance genes
EP3980540A4 (de)	2019-06-06	2023-11-01	Arrowhead Pharmaceuticals, Inc.	Verfahren zur behandlung von alpha-1-antitrypsin-mangel (aatd)
BR112021025130A2 (pt)	2019-06-14	2022-03-15	Scripps Research Inst	Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos
ES3048358T3 (en)	2019-07-26	2025-12-10	Ionis Pharmaceuticals Inc	Compounds and methods for modulating gfap
EP4007811A2 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4007812A1 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TW202543680A (zh)	2019-08-15	2025-11-16	美商欣爍克斯公司	使用il-2接合物之免疫腫瘤學組合療法
KR20220062517A (ko)	2019-08-15	2022-05-17	아이오니스 파마수티컬즈, 인코포레이티드	결합 변형된 올리고머 화합물 및 이의 용도
PH12022500004A1 (en)	2019-08-23	2023-04-03	Synthorx Inc	Il-15 conjugates and uses thereof
US20220290152A1 (en)	2019-09-03	2022-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
MX2022002740A (es)	2019-09-10	2022-03-25	Synthorx Inc	Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
US12319711B2 (en)	2019-09-20	2025-06-03	Northwestern University	Spherical nucleic acids with tailored and active protein coronae
WO2021067747A1 (en)	2019-10-04	2021-04-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
JP7757277B2 (ja)	2019-10-14	2025-10-21	アストラゼネカ・アクチエボラーグ	Ｐｎｐｌａ３発現のモジュレーター
WO2021076828A1 (en)	2019-10-18	2021-04-22	Alnylam Pharmaceuticals, Inc.	Solute carrier family member irna compositions and methods of use thereof
BR112022007540A2 (pt)	2019-10-22	2022-07-12	Alnylam Pharmaceuticals Inc	Composições de irna de componente complementar c3 e métodos de uso das mesmas
US12378560B2 (en)	2019-10-29	2025-08-05	Northwestern University	Sequence multiplicity within spherical nucleic acids
EP4052035A1 (de)	2019-10-31	2022-09-07	The Trustees of Wheaton College	Entwurf und charakterisierung von mehrschichtigen strukturen zur unterstützung von lipiddoppelschichten
CN114728018B (zh)	2019-11-01	2024-07-19	阿尔尼拉姆医药品有限公司	亨廷顿(HTT)iRNA药剂组合物及其使用方法
WO2021087325A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
AU2020380275A1 (en)	2019-11-04	2022-04-14	Synthorx, Inc.	Interleukin 10 conjugates and uses thereof
TW202526019A (zh)	2019-11-13	2025-07-01	美商阿尼拉製藥公司	用於治療血管收縮素原相關病症之方法及組成物
EP4061945A1 (de)	2019-11-22	2022-09-28	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
CA3159501A1 (en)	2019-11-27	2021-06-03	Brian Joseph CAFFERTY	Methods of synthesizing rna molecules
TWI897902B (zh)	2019-12-13	2025-09-21	美商阿尼拉製藥公司	人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法
WO2021126734A1 (en)	2019-12-16	2021-06-24	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP4077674A1 (de)	2019-12-18	2022-10-26	Alia Therapeutics S.R.L.	Zusammensetzungen und verfahren zur behandlung von retinitis pigmentosa
WO2021142245A1 (en)	2020-01-10	2021-07-15	Translate Bio, Inc.	Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
US12503695B2 (en)	2020-01-27	2025-12-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	RAB13 and NET1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
MX2022009763A (es)	2020-02-10	2022-09-09	Alnylam Pharmaceuticals Inc	Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
WO2021167841A1 (en)	2020-02-18	2021-08-26	Alnylam Pharmaceuticals, Inc.	Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
US11920136B2 (en)	2020-02-28	2024-03-05	Tallac Therapeutics, Inc.	Transglutaminase-mediated conjugation
PH12022552258A1 (en)	2020-02-28	2023-11-20	Ionis Pharmaceuticals Inc	Compounds and methods for modulating smn2
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
WO2021178736A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
EP4127171A2 (de)	2020-03-30	2023-02-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
US12534731B2 (en)	2020-04-01	2026-01-27	Alnylam Pharmaceuticals, Inc.	Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
CA3179411A1 (en)	2020-04-06	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing myoc expression
IL297130A (en)	2020-04-07	2022-12-01	Alnylam Pharmaceuticals Inc	Compositions and methods for silencing scn9a expression
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA3176196A1 (en)	2020-04-21	2021-10-28	Flagship Pioneering, Inc.	Bifunctional molecules and methods of using thereof
WO2021222065A1 (en)	2020-04-27	2021-11-04	Alnylam Pharmaceuticals, Inc.	Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
EP4142738A1 (de)	2020-04-30	2023-03-08	Alnylam Pharmaceuticals, Inc.	Komplementfaktor-b (cfb)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230005933A (ko)	2020-05-01	2023-01-10	아이오니스 파마수티컬즈, 인코포레이티드	Atxn1을 조정하는 화합물 및 방법
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231691A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4150088A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
WO2021231698A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4153746A1 (de)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
US11408000B2 (en)	2020-06-03	2022-08-09	Triplet Therapeutics, Inc.	Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
US20230203496A1 (en)	2020-06-09	2023-06-29	Alnylam Pharmaceuticals, Inc.	Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
EP4162050A1 (de)	2020-06-09	2023-04-12	Alnylam Pharmaceuticals, Inc.	Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
AU2021292296A1 (en)	2020-06-18	2023-01-19	Alnylam Pharmaceuticals, Inc.	Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
AR122722A1 (es)	2020-06-24	2022-09-28	Vir Biotechnology Inc	Anticuerpos que neutralizan el virus de la hepatitis b y sus usos
JP2023531509A (ja)	2020-06-25	2023-07-24	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートおよび抗ｅｇｆｒ抗体を用いる免疫腫瘍学併用療法
IL298530A (en)	2020-06-29	2023-01-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating plp1
KR20230043914A (ko)	2020-07-28	2023-03-31	아이오니스 파마수티컬즈, 인코포레이티드	App 발현을 감소시키기 위한 화합물 및 방법
TW202221123A (zh)	2020-08-07	2022-06-01	美商Ionis製藥公司	調節ｓｃｎ２ａ之化合物及方法
TW202227102A (zh)	2020-09-22	2022-07-16	瑞典商阿斯特捷利康公司	治療脂肪肝病之方法
EP4217489A1 (de)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4222264A1 (de)	2020-09-30	2023-08-09	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von amyotropher lateralsklerose
EP3978608A1 (de)	2020-10-05	2022-04-06	SQY Therapeutics	Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
TW202229552A (zh)	2020-10-05	2022-08-01	美商艾拉倫製藥股份有限公司	Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法
CN116615235A (zh)	2020-10-09	2023-08-18	得克萨斯州大学系统董事会	融合前稳定的hmpv f蛋白
IL301611A (en)	2020-10-09	2023-05-01	Synthorx Inc	Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
JP2023546010A (ja)	2020-10-09	2023-11-01	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートを用いた免疫腫瘍療法
AU2021365822A1 (en)	2020-10-21	2023-06-08	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
WO2022087329A1 (en)	2020-10-23	2022-04-28	Alnylam Pharmaceuticals, Inc.	Mucin 5b (muc5b) irna compositions and methods of use thereof
CN116761885A (zh)	2020-10-23	2023-09-15	斯克利普斯研究所	包含非天然核苷酸的多核苷酸的逆转录
WO2022103999A1 (en)	2020-11-13	2022-05-19	Alnylam Pharmaceuticals, Inc.	COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP7820374B2 (ja)	2020-11-18	2026-02-25	アイオーニスファーマシューティカルズ，インコーポレーテッド	アンジオテンシノーゲン発現を調節するための化合物及び方法
CA3202708A1 (en)	2020-11-23	2022-05-27	Alpha Anomeric Sas	Nucleic acid duplexes
US11987795B2 (en)	2020-11-24	2024-05-21	The Broad Institute, Inc.	Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
EP4256053A1 (de)	2020-12-01	2023-10-11	Alnylam Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
GB2603454A (en)	2020-12-09	2022-08-10	Ucl Business Ltd	Novel therapeutics for the treatment of neurodegenerative disorders
US12018261B2 (en)	2020-12-18	2024-06-25	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating factor XII
BR112023012377A2 (pt)	2020-12-23	2023-10-24	Flagship Pioneering Innovations Vi Llc	Composições de trems modificadas e usos das mesmas
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202245843A (zh)	2021-02-12	2022-12-01	美商欣爍克斯公司	Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
EP4291654A2 (de)	2021-02-12	2023-12-20	Alnylam Pharmaceuticals, Inc.	Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen
TW202302148A (zh)	2021-02-12	2023-01-16	美商欣爍克斯公司	使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
WO2022182864A1 (en)	2021-02-25	2022-09-01	Alnylam Pharmaceuticals, Inc.	Prion protein (prnp) irna compositions and methods and methods of use thereof
JP2024515423A (ja)	2021-02-26	2024-04-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法
AU2022231003A1 (en)	2021-03-04	2023-09-14	Alnylam Pharmaceuticals, Inc.	Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
US20220288181A1 (en)	2021-03-12	2022-09-15	Northwestern University	Antiviral vaccines using spherical nucleic acids
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
IL307239A (en)	2021-03-29	2023-11-01	Alnylam Pharmaceuticals Inc	Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
WO2022212153A1 (en)	2021-04-01	2022-10-06	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
US20250270575A1 (en)	2021-04-07	2025-08-28	Neoplants Sas	Compositions and methods for indoor air remediation
WO2022226344A1 (en)	2021-04-22	2022-10-27	The Board Of Regents Of The University Of Texas System	All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo
BR112023022284A2 (pt)	2021-04-26	2023-12-26	Alnylam Pharmaceuticals Inc	Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
EP4330396A1 (de)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022235537A1 (en)	2021-05-03	2022-11-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
EP4341401A1 (de)	2021-05-18	2024-03-27	Alnylam Pharmaceuticals, Inc.	Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4341405A1 (de)	2021-05-20	2024-03-27	Korro Bio, Inc.	Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
JP2024522996A (ja)	2021-06-02	2024-06-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
TW202313679A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
BR112023025224A2 (pt)	2021-06-04	2024-02-27	Alnylam Pharmaceuticals Inc	Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
EP4351541A2 (de)	2021-06-08	2024-04-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit morbus stargardt und/oder retinal-bindendem protein 4 (rbp4)
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
IL308896A (en)	2021-06-11	2024-01-01	Bayer Ag	Type v rna programmable endonuclease systems
EP4355759A4 (de)	2021-06-18	2026-05-13	Ionis Pharmaceuticals Inc	Verbindungen und verfahren zur reduzierung der ifnar1-expression
US20250034564A1 (en)	2021-06-29	2025-01-30	Korro Bio, Inc.	Methods and Compositions for ADAR-Mediated Editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
MX2023015489A (es)	2021-06-30	2024-01-19	Alnylam Pharmaceuticals Inc	Metodos y composiciones para tratar un trastorno asociado al angiotensinogeno (agt).
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
JP2024528701A (ja)	2021-07-23	2024-07-30	アルナイラムファーマシューティカルズ，インコーポレイテッド	ベータカテニン（ＣＴＮＮＢ１）ｉＲＮＡ組成物およびその使用方法
JP2024529437A (ja)	2021-07-29	2024-08-06	アルナイラムファーマシューティカルズ，インコーポレイテッド	３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
TW202328445A (zh)	2021-08-03	2023-07-16	美商艾拉倫製藥股份有限公司	甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其使用方法
PE20241132A1 (es)	2021-08-04	2024-05-24	Alnylam Pharmaceuticals Inc	Composiciones de arni y metodos para silenciar el angiotensinogeno (agt)
IL310407A (en)	2021-08-13	2024-03-01	Alnylam Pharmaceuticals Inc	Factor XII (F12) IRNA compositions and methods of using them
MX2024002440A (es)	2021-08-31	2024-03-08	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
US11833221B2 (en)	2021-09-01	2023-12-05	Ionis Pharmaceuticals, Inc.	Oligomeric compounds for reducing DMPK expression
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
EP4405478A1 (de)	2021-09-20	2024-07-31	Alnylam Pharmaceuticals, Inc.	Inhibinuntereinheits-beta-e (inhbe)-modulatorzusammensetzungen und verfahren zur verwendung davon
MX2024003519A (es)	2021-09-24	2024-04-01	Alnylam Pharmaceuticals Inc	Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
AU2022356427A1 (en)	2021-09-30	2024-05-09	Akouos, Inc.	Compositions and methods for treating kcnq4-associated hearing loss
CA3233755A1 (en)	2021-10-01	2023-04-06	Adarx Pharmaceuticals, Inc.	Prekallikrein-modulating compositions and methods of use thereof
AU2022370009A1 (en)	2021-10-22	2024-05-16	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
CA3234636A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
TW202334418A (zh)	2021-10-29	2023-09-01	美商艾拉倫製藥股份有限公司	杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
US20250066790A1 (en)	2021-11-10	2025-02-27	University Of Rochester	Antisense oligonucleotides for modifying protein expression
CA3237769A1 (en)	2021-11-10	2023-05-19	University Of Rochester	Gata4-targeted therapeutics for treatment of cardiac hypertrophy
GB202117758D0 (en)	2021-12-09	2022-01-26	Ucl Business Ltd	Therapeutics for the treatment of neurodegenerative disorders
WO2023122573A1 (en)	2021-12-20	2023-06-29	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
CA3243006A1 (en)	2021-12-21	2025-02-27	Alia Therapeutics Srl	TYPE II CAS PROTEINS AND THEIR APPLICATIONS
CA3243301A1 (en)	2021-12-23	2023-06-29	Bayer Aktiengesellschaft	NEW SMALL PROGRAMMABLE TYPE V RNA ENDONUCLEASE SYSTEMS
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
EP4469575A2 (de)	2022-01-24	2024-12-04	Alnylam Pharmaceuticals, Inc.	Enzym-irna-wirkstoffzusammensetzungen für den heparinsulfatbiosyntheseweg und verfahren zur verwendung davon
US12037616B2 (en)	2022-03-01	2024-07-16	Crispr Therapeutics Ag	Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
WO2023237587A1 (en)	2022-06-10	2023-12-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
JP2025527531A (ja)	2022-08-18	2025-08-22	アルナイラムファーマシューティカルズ，インコーポレイテッド	ユニバーサル非標的ｓｉｒｎａ組成物およびその使用方法
JP2025530741A (ja)	2022-08-29	2025-09-17	ユニヴァーシティオヴロチェスター	アンチセンスオリゴヌクレオチドベースの抗線維化治療剤
TW202424193A (zh)	2022-09-15	2024-06-16	美商艾拉倫製藥股份有限公司	第１３型１７β－羥基類固醇去氫酶（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物及其使用方法
CA3267752A1 (en)	2022-09-16	2024-03-21	Alia Therapeutics Srl	ENQP TYPE II CAS PROTEINS AND THEIR APPLICATIONS
CN120239607A (zh)	2022-09-23	2025-07-01	Ionis制药公司	用于降低mecp2表达的化合物和方法
WO2024105162A1 (en)	2022-11-16	2024-05-23	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
EP4634376A2 (de)	2022-12-13	2025-10-22	Bayer Aktiengesellschaft	Gentechnisch hergestellte typ-v-rna-programmierbare endonukleasen und deren verwendungen
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
EP4648796A2 (de)	2023-01-09	2025-11-19	Board of Regents, The University of Texas System	Präfusionsstabilisierte menschliche parainfluenzavirus 3f proteine
JP2026502531A (ja)	2023-01-11	2026-01-23	アリアセラピューティクスエスアールエル	Ｉｉ型ｃａｓタンパク質およびその適用
AU2024217843A1 (en)	2023-02-09	2025-07-31	Alnylam Pharmaceuticals, Inc.	Reversir molecules and methods of use thereof
WO2024170778A1 (en)	2023-02-17	2024-08-22	Anjarium Biosciences Ag	Methods of making dna molecules and compositions and uses thereof
TW202444349A (zh)	2023-03-20	2024-11-16	美商欣爍克斯公司	使用ｉｌ－２綴合物之癌症療法
US12383615B2 (en)	2023-03-23	2025-08-12	Carbon Biosciences, Inc.	Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
WO2024196965A1 (en)	2023-03-23	2024-09-26	Carbon Biosciences, Inc.	Parvovirus compositions and related methods for gene therapy
UY40699A (es)	2023-04-05	2024-08-30	Ionis Pharmaceuticals Inc	Compuestos y métodos para reducir la expresión de pln
WO2024208249A1 (zh)	2023-04-06	2024-10-10	上海舶望制药有限公司	5'-膦酸酯修饰的核苷类似物及其制备的寡核苷酸
CN121285630A (zh)	2023-04-20	2026-01-06	阿达尔克斯制药有限公司	Mapt调节组合物及其使用方法
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
KR20260021635A (ko)	2023-05-12	2026-02-13	아다르엑스 파마슈티컬스, 인크.	Nmda 리간드 접합 화합물 및 이의 용도
WO2024243062A1 (en)	2023-05-19	2024-11-28	Streck Llc	Detection of antibiotic resistance genes
IL324720A (en)	2023-05-26	2026-01-01	Adarx Pharmaceuticals Inc	SOD1 modulators and methods of using them
CN121712891A (zh)	2023-06-20	2026-03-20	阿达尔克斯制药有限公司	Lrrk2调节组合物及其使用方法
WO2025003344A1 (en)	2023-06-28	2025-01-02	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
WO2025015338A1 (en)	2023-07-13	2025-01-16	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
KR20260044219A (ko)	2023-07-21	2026-04-01	매로우 테라퓨틱스, 인크.	조혈 세포 표적화 접합체 및 관련 방법
US20250092426A1 (en)	2023-07-25	2025-03-20	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
AU2024297923A1 (en)	2023-07-25	2026-01-22	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
IL326321A (en)	2023-08-04	2026-04-01	Alnylam Pharmaceuticals Inc	Methods and compositions for treating CTNNB1-related disorders
IL327100A (en)	2023-09-15	2026-05-01	Praxis Prec Medicines Inc	Alsonarsen/PRAX-22 for use in the treatment of SCN2A-related disorders
WO2025072331A1 (en)	2023-09-26	2025-04-03	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
GB202314724D0 (en)	2023-09-26	2023-11-08	Astrazeneca Ab	compounds and methods for reducing psd3 expression
WO2025072713A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Polymyxins for delivery of agents to the kidney
AU2024348221A1 (en)	2023-09-27	2026-04-30	Judo Bio Inc.	Aminoglycosides for delivery of agents to the kidney
WO2025072672A2 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Slc6a19-targeting modulatory nucleic acid agents
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
CN121969744A (zh)	2023-10-06	2026-05-01	拜耳公司	工程化v型rna可编程核酸内切酶及其用途
WO2025096809A1 (en)	2023-10-31	2025-05-08	Korro Bio, Inc.	Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025117877A2 (en)	2023-12-01	2025-06-05	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025158385A1 (en)	2024-01-25	2025-07-31	Genzyme Corporation	Pegylated il-2 for suppressing adaptive immune response to gene therapy
EP4671372A3 (de)	2024-01-29	2026-03-11	Arnatar Therapeutics, Inc	Translationsverstärkende nukleinsäureverbindungen: aso-gekoppelte translation - hochregulierung 1 (act-up1) und verwendungen davon
WO2025178854A2 (en)	2024-02-19	2025-08-28	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
WO2025199231A2 (en)	2024-03-20	2025-09-25	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025207517A2 (en)	2024-03-25	2025-10-02	Synthorx, Inc.	Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides
GB202404290D0 (en)	2024-03-26	2024-05-08	Senisca Ltd	Novel oligoncleotides
WO2025210147A1 (en)	2024-04-04	2025-10-09	Alia Therapeutics Srl	Type v cas proteins and applications thereof
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026050243A1 (en)	2024-08-26	2026-03-05	Korro Bio, Inc.	Galnac conjugated oligonucleotides for rna editing
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
WO2026062247A1 (en)	2024-09-20	2026-03-26	Astrazeneca Ab	Liquid-phase oligonucleotide synthesis using 2-(2-nitrophenyl)propyloxycarbonyl (nppoc) as a protecting group
WO2026064739A1 (en)	2024-09-23	2026-03-26	Carbon Biosciences, Inc.	Parvovirus compositions and related methods for gene therapy
WO2026064736A1 (en)	2024-09-23	2026-03-26	Carbon Biosciences, Inc.	Parvovirus compositions and related methods for gene therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3870700A (en) *	1973-05-29	1975-03-11	Miles Lab	2-halogeno-2-deoxy-5-(substituted)uridines
US4211773A (en) *	1978-10-02	1980-07-08	Sloan Kettering Institute For Cancer Research	5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4711955A (en) *	1981-04-17	1987-12-08	Yale University	Modified nucleotides and methods of preparing and using same
GB8517402D0 (en) *	1985-07-10	1985-08-14	Wellcome Found	Treatment of viral infections
DE3606634A1 (de) *	1986-02-28	1987-09-03	Mack Chem Pharm	Isohexid-nucleoside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5047519A (en) *	1986-07-02	1991-09-10	E. I. Du Pont De Nemours And Company	Alkynylamino-nucleotides
GB8629892D0 (en) *	1986-12-15	1987-01-28	Wellcome Found	Antiviral compounds

1988
- 1988-06-24 DE DE3851889T patent/DE3851889T2/de not_active Expired - Lifetime
- 1988-06-24 CA CA000570427A patent/CA1340032C/en not_active Expired - Fee Related
- 1988-06-24 AT AT88905594T patent/ATE113059T1/de not_active IP Right Cessation
- 1988-06-24 NZ NZ225176A patent/NZ225176A/xx unknown
- 1988-06-24 JP JP63505657A patent/JP2828642B2/ja not_active Expired - Lifetime
- 1988-06-24 WO PCT/AU1988/000207 patent/WO1988010264A1/en not_active Ceased
- 1988-06-24 AU AU19909/88A patent/AU598946B2/en not_active Expired
- 1988-06-24 EP EP88905594A patent/EP0366685B1/de not_active Expired - Lifetime
1993
- 1993-05-27 US US08/068,604 patent/US5552540A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO1988010264A1 (en)	1988-12-29
JP2828642B2 (ja)	1998-11-25
EP0366685A1 (de)	1990-05-09
JPH02504144A (ja)	1990-11-29
DE3851889D1 (de)	1994-11-24
AU1990988A (en)	1989-01-19
US5552540A (en)	1996-09-03
NZ225176A (en)	1990-09-26
EP0366685B1 (de)	1994-10-19
EP0366685A4 (en)	1991-03-20
AU598946B2 (en)	1990-07-05
DE3851889T2 (de)	1995-04-13
CA1340032C (en)	1998-09-08

Legal Events

Date	Code	Title	Description
1995-04-15	UEP	Publication of translation of european patent specification
2008-09-15	EELA	Cancelled due to lapse of time

Publication	Publication Date	Title
DE3851889D1 (de)	1994-11-24	Nukleosid-derivate.
DK345285A (da)	1986-02-03	Diphosphonsyrederivater, fremgangsmaade til deres fremstilling og laegemidler, der indeholder disse forbindelser
ES2156994T3 (es)	2001-08-01	Sustratos para beta-lactamasa y usos de estos sustratos.
ATE127801T1 (de)	1995-09-15	Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung.
FI864614A0 (fi)	1986-11-12	Nya difosfonsyraderivat, foerfaranden foer framstaellning av dessa samt laekemedel innehaollande dessa foereningar.
ES2141727T3 (es)	2000-04-01	Derivados de 10-desacetoxitaxol.
ES8706163A1 (es)	1987-06-01	Procedimiento para la fabricacion de nuevos derivados nu- cleosidos
AR241195A1 (es)	1992-01-31	Compuestos de 1-(2'-fenilamino-4'-cloro-1',3',5'-triazin-6'-il)amino-4-fenilazo-o -4-naftilazo-benceno o -naftaleno hidrosolubles, procedimiento para su preparacion y preparados que los contienen
SE7706392L (sv)	1977-12-10	N-fosfonometylenmonoaminoalkanmono- och -polyfosfonsyror respektive n-fosfonometylendiaminoalkanpolyfosfonsyror samt sett for deras framstellning
EP0347930A3 (de)	1992-01-02	Metalloxid enthaltende Mischung
DE68910655D1 (de)	1993-12-16	Kesselsteinverhütung.
DK341985A (da)	1986-01-28	Antihoste og slimregulerende 2-substituerede thiazolidiner
KR840005733A (ko)	1984-11-16	무라밀 펩타이드의 제조방법
CO4960660A1 (es)	2000-09-25	Derivados de 5-aroil-pirrol-2-ilmetilareno, composiciones farmaceuticas que las contienen y metodos para la preparacion de estos compuestos
ES8700242A1 (es)	1986-09-16	Un procedimiento para preparar un derivado de dihidropirida-zinona
EP0547231A4 (en)	1994-06-08	Phospholipase a 2? inhibitor
JPS6485985A (en)	1989-03-30	Synthesis of aminomethylenephosphonoalkylphosphinates
MY101173A (en)	1991-07-31	Non-radioactive biological probes.
TW328083B (en)	1998-03-11	New derivatives of β-methoxy acrylic acid, their preparation process and their use as pesticides
IE800912L (en)	1980-11-03	Bis(4-demethoxydaunorubicin) dihydrazones
DK558786A (da)	1987-05-24	Basisk substituerede pyridinforbindelser, fremstilling deraf, samt laegemidler, indeholdende disse
ATE121465T1 (de)	1995-05-15	Verfahren zur korrosionsinhibierung.
PE25195A1 (es)	1995-09-29	Sintesis de l-aspartil-d-aminoalcanoil-(s)-o-alquilbencil amida utilizada como endulzante artificial
ATE154359T1 (de)	1997-06-15	2'-methylidenpyrimidinnukleosidverbindungen, ihre verwendung und verfahren zu ihrer herstellung
ES472429A1 (es)	1979-04-01	Un procedimiento para la preparacion de compuestos de 4-de-soxi-4-amino-eritromicina a.